Preprints are all around us – but are they relevant and useful or too risky for industry-sponsored research? Two sessions at the 14th Annual Meeting of ISMPP held in Washington this month kicked off the first major public discussions on preprints in our medical communications community.
Time to embrace change in medical publishing?
At this year’s ISMPP European meeting, a panel of Open Pharma members discussed open access, preprints and post-publication peer review, and the possibility of utilizing these tools to make the publishing of pharmaceutical research faster and more transparent.
Open Pharma: a publisher’s perspective
We aimed to gain insight into the publishing industry’s perspective on new innovations in the field, as their collaboration will be key to implementing changes.
Weekly digest: the latest news on topics important to Open Pharma
Featuring the whodunit on the demise of Beall’s list, The Royal Society’s ORCID mandate and how authors and reviewers have responded to PeerJ’s optional open peer review. Who killed Beall's list? via The Chronicle of Higher Education A review of the prime suspects in the demise of Beall’s list, and a discussion on where open … Continue reading Weekly digest: the latest news on topics important to Open Pharma
When will preprints take off in medicine?
Use of preprints is increasing rapidly, with the number of preprints posted to repositories each month almost doubling in the past year
Summary report from the Open Pharma workstream meetings in July
Summary report from the Open Pharma workstream meetings in July
Update on Open Pharma workstreams: June 2017
Since the launch of Open Pharma in January 2017, groups of stakeholders have convened on a monthly basis to explore how to implement positive changes in scientific publishing across four key areas: open access; ORCID, CRediT and Convey; preprints and post-publication peer review; and layered publication platforms. The collated key insights and next steps from … Continue reading Update on Open Pharma workstreams: June 2017
Overview: Open Pharma workstream kick-off meetings
The first Open Pharma workstream meetings took place last week. The collated key insights and next steps can be found below. If you would like to get involved, please refer to our contacts page. Workstream 1: Open access Key insights Next steps Before driving change, we need to define what we mean by open access Define … Continue reading Overview: Open Pharma workstream kick-off meetings
Why not use a novel publishing platform?
Questions from delegates at ISMPP US 2017 guided poster tour highlight practical issues presenting barriers to uptake of innovative platforms
Preprints are beginning to arrive in biology, will medicine be next?
Preprints, long used in physics, astronomy and mathematics, finally seem to be catching on in the life sciences. A recent online seminar, hosted by internet reference linking organization Crossref, showcased the benefits that preprints can lend to biology researchers. Preprints serve to bridge the often lengthy period between submission to a peer-reviewed journal and official … Continue reading Preprints are beginning to arrive in biology, will medicine be next?